Tempus AI, Inc. (TEM) Announces Strategic Deal with Merck to Fast-Track AI-Driven Precision Medicine

Tempus AI, Inc. (NASDAQ:TEM) is among the ARK Invest Stock Portfolio: Top 10 Stock Picks for 2026. On March 3, the company announced a strategic partnership with Merck to fast-track the development of AI-driven precision medicine and support the pharma-maker’s oncology portfolio and other therapeutic offerings.

As part of the agreement, Merck will leverage Tempus AI, Inc. (NASDAQ:TEM)’s de-identified data and Lens Platform and Workspaces technologies to generate new discoveries and accelerate the development and effective use of candidate therapies on a large scale.

In other news, on February 25, JPMorgan analyst Casey Woodring slashed the stock’s price target to $60 from $80, with a Neutral rating, following the company’s Q4 earnings call a day prior.

Tempus AI, Inc. (TEM) Announces Strategic Deal with Merck to Fast-Track AI-Driven Precision Medicine

Photo from Iovance Biotherapeutics website

According to TipRanks, the firm cited Tempus AI, Inc.’s (NASDAQ:TEM) ‘clouded visibility’ on data upside and a revision to its outlook for Ambry as the reason behind the adjustment.

As of the close of business on March 4, the stock is a Moderate Buy, with an average upside potential of 52.5%.

Tempus AI, Inc. (NASDAQ:TEM) is a healthcare technology company that uses artificial intelligence to advance precision medicine.

While we acknowledge the risk and potential of TEM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TEM and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 40 Most Popular Stocks Among Hedge Funds Heading Into 2026 and 10 Best Magic Formula Stocks for 2026.

Disclosure: None. Follow Insider Monkey on Google News.